JP2020507596A - 膀胱癌の抗ｐｄ−ｌ１抗体治療 - Google Patents

膀胱癌の抗ｐｄ−ｌ１抗体治療 Download PDF

Info

Publication number
JP2020507596A
JP2020507596A JP2019543851A JP2019543851A JP2020507596A JP 2020507596 A JP2020507596 A JP 2020507596A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2020507596 A JP2020507596 A JP 2020507596A
Authority
JP
Japan
Prior art keywords
subject
antigen
bladder cancer
binding fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019543851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507596A5 (cg-RX-API-DMAC7.html
Inventor
クールラント，ジョン
ブレイク−ハスキンス，ジョン，アンドリュー
ザジャック，マグダレーナ
レベラット，マーロン
グプタ，アショク
ホー，トニー
ウォーカー，ジル
ジン，シャオピン
モリス，シャノン
イアンノーネ，ロバート
シ，リー
ダル，モハメド
ベン，ヨン
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2020507596A publication Critical patent/JP2020507596A/ja
Publication of JP2020507596A5 publication Critical patent/JP2020507596A5/ja
Priority to JP2023216425A priority Critical patent/JP2024038034A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019543851A 2017-02-16 2018-02-16 膀胱癌の抗ｐｄ−ｌ１抗体治療 Pending JP2020507596A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023216425A JP2024038034A (ja) 2017-02-16 2023-12-22 膀胱癌の抗ｐｄ－ｌ１抗体治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
US62/459,700 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023216425A Division JP2024038034A (ja) 2017-02-16 2023-12-22 膀胱癌の抗ｐｄ－ｌ１抗体治療

Publications (2)

Publication Number Publication Date
JP2020507596A true JP2020507596A (ja) 2020-03-12
JP2020507596A5 JP2020507596A5 (cg-RX-API-DMAC7.html) 2021-04-01

Family

ID=63169615

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543851A Pending JP2020507596A (ja) 2017-02-16 2018-02-16 膀胱癌の抗ｐｄ−ｌ１抗体治療
JP2023216425A Pending JP2024038034A (ja) 2017-02-16 2023-12-22 膀胱癌の抗ｐｄ－ｌ１抗体治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023216425A Pending JP2024038034A (ja) 2017-02-16 2023-12-22 膀胱癌の抗ｐｄ－ｌ１抗体治療

Country Status (12)

Country Link
US (2) US20190359715A1 (cg-RX-API-DMAC7.html)
EP (1) EP3582805A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020507596A (cg-RX-API-DMAC7.html)
KR (3) KR20190117014A (cg-RX-API-DMAC7.html)
CN (2) CN118001389A (cg-RX-API-DMAC7.html)
AU (2) AU2018221822A1 (cg-RX-API-DMAC7.html)
CA (1) CA3052652A1 (cg-RX-API-DMAC7.html)
EA (1) EA201991870A1 (cg-RX-API-DMAC7.html)
IL (3) IL302777A (cg-RX-API-DMAC7.html)
MA (1) MA47509A (cg-RX-API-DMAC7.html)
SG (1) SG11201907211TA (cg-RX-API-DMAC7.html)
WO (1) WO2018152415A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024038034A (ja) * 2017-02-16 2024-03-19 メディミューン，エルエルシー 膀胱癌の抗ｐｄ－ｌ１抗体治療

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456756B (zh) * 2014-05-13 2021-04-23 免疫医疗有限公司 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
WO2021234150A1 (en) * 2020-05-21 2021-11-25 Astrazeneca Ab Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196298A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
CN106456756B (zh) * 2014-05-13 2021-04-23 免疫医疗有限公司 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
BR112017018234A2 (pt) * 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
BR112018071287A2 (pt) * 2016-04-25 2019-02-19 Medimmune, Llc composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4
CN118001389A (zh) * 2017-02-16 2024-05-10 免疫医疗有限责任公司 膀胱癌的抗pd-l1抗体治疗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196298A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Therapeutic and diagnolstic methods for cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER TREATMENT REVIEWS, vol. 54, JPN6022002193, 2 February 2017 (2017-02-02), pages 58 - 67, ISSN: 0005132707 *
EUROPEAN JOURNAL OF CANCER, 2016, VOL.68, PP.156-162, JPN6022002196, ISSN: 0004689650 *
J. CLIN. ONCOL., 2016, VOL.34, SUPPL., P.TPS6101, JPN6022002198, ISSN: 0004925620 *
JOURNAL OF CLINICAL ONCOLOGY, 2016, VOL.34, NO.26, PP.3119-3125, JPN6022002195, ISSN: 0004689649 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024038034A (ja) * 2017-02-16 2024-03-19 メディミューン，エルエルシー 膀胱癌の抗ｐｄ－ｌ１抗体治療

Also Published As

Publication number Publication date
AU2025201227A1 (en) 2025-03-13
CA3052652A1 (en) 2018-08-23
SG11201907211TA (en) 2019-09-27
US20220332828A1 (en) 2022-10-20
AU2018221822A1 (en) 2019-09-26
US20190359715A1 (en) 2019-11-28
JP2024038034A (ja) 2024-03-19
EP3582805A4 (en) 2021-03-10
IL268460A (en) 2019-09-26
CN118001389A (zh) 2024-05-10
IL320916A (en) 2025-07-01
KR20230145547A (ko) 2023-10-17
EP3582805A1 (en) 2019-12-25
WO2018152415A1 (en) 2018-08-23
CN110290803A (zh) 2019-09-27
KR20250025517A (ko) 2025-02-21
IL302777A (en) 2023-07-01
MA47509A (fr) 2019-12-25
KR20190117014A (ko) 2019-10-15
EA201991870A1 (ru) 2020-02-12

Similar Documents

Publication Publication Date Title
JP7568698B2 (ja) 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
JP2022068352A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
EP4386005A2 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
US20160347836A1 (en) Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
JP2021510697A (ja) がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療
CN115942973A (zh) 用于黑色素瘤的lag-3拮抗剂疗法
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
US20220154296A1 (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
WO2021160152A1 (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN113677402A (zh) 治疗肿瘤的方法
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
TW202436335A (zh) 治療表現ｄｌｌ３的癌症之方法
CN118785922A (zh) 靶向dll3的癌症治疗
HK40066498A (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230822